Dutchy27 Nov 2013 23:31
one or two further comments:
The Scheme document makes clear at several points that it is important, both to satisfy the UK Court and for the future of XEN, that shareholders use their vote at or before the EGM on 17th December. I won't presume to advise on how to vote but will say that the whole focus for XEN over the past year and more has been towards US listing. It makes sense in every way, and by contrast AIM has done and would not do us any favours were the vote to be in the negative.
Let's remember too that, even if we did not complete our US move (unlikely in my view), XEN has received assurances from its major shareholders for continued funding. Note this from Interims, 30th Sept last:
"US capital markets for biotech have been buoyant throughout 2013 and, while conditions remain subject to rapid change, based on recent soundings in the US, the Directors are confident of raising the required quantum of new capital in a timely manner post the Company's transition to the US.....If the initial required funding is not received....the Board has an available interim strategy, which includes deferring internal development costs and obtaining interim funding support from existing key shareholders, both of which could be utilised to appropriately manage the resulting working capital position of the Group".